Related: FDA says injectable PrEP a ‘breakthrough’ therapy as it pends approvalThe participants took the drug once a month for six months.
After this period, follow-ups were done to monitor how quickly the drug left their system.The study found that, eight weeks after taking their last tablet, those who took either 60mg or 120mg of islatravir still had enough of the medication in their bloodstream to prevent HIV infection (known as the PK threshold).
This fell further at the 12-week follow-up.“The 24-week analysis of investigational, once-monthly oral islatravir not only builds upon the PK data we have already seen, but also provides encouraging support for the safety and tolerability profile of this HIV-1 PrEP regimen,” said Dr.